Bebtelovimab

Important Information About Bebtelovimab

Bebtelovimab has received Emergency Use Authorization (EUA) allowing healthcare providers to administer bebtelovimab for outpatient treatment of mild to moderate COVID-19 in adults and children age 12 years and older,

who are at high risk for progressing to severe COVID-19 and/or hospitalization and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Emergency Use Authorization of Bebtelovimab

On Feb. 11, 2022, Eli Lilly and Company received an EUA from the U.S. Food and Drug Administration (FDA) for its COVID-19 monoclonal antibody therapeutic bebtelovimab. Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

Allocation and Distribution of Bebtelovimab

In alignment with the terms of the EUA for bebtelovimab, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response will oversee the fair and equitable allocation and distribution of this product.

HHS will allocate patient courses of bebtelovimab on a recurring basis as product becomes available from the manufacturer. The initial 50,000 patient courses were made available on Monday, Feb. 14 to state and territorial health departments. Health departments will, in turn, determine which healthcare facilities receive the drug. Recurring allocations to state and territorial health departments are determined using a disease-based methodology that considers COVID-19 case counts and hospitalizations within a jurisdiction.

You may read the Original article at the following link

https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bebtelovimab/Pages/default.aspx